missing translation for 'onlineSavingsMsg'
Learn More

Gibco™ Human Noggin Recombinant Protein, PeproTech®

Recombinant Protein

Supplier:  Gibco™ 12010C01M

 Afficher plus de versions de ce produit

Numéro de catalogue. 12-010-C01M


Il en reste null
Découvrez plus d'offres spéciales

Description

Description

120-10C-1MG will be provided as 2 x 500 μg (120-10C-500UG). Recombinant Human Noggin is a 46 kDa disulfide-linked homodimer consisting of two 205 amino acid polypeptide chains. Monomeric glycosylated noggin migrates at an apparent molecular weight of approximately 28.0-33.0 kDa by SDS PAGE analysis under reducing conditions. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Noggin is involved in numerous developmental processes, such as neural tube fusion and joint formation. The morphogenesis of organs is initiated by a downgrowth from a layer of epithelial stem cells. This process is achieved through the receipt of signals from 1) a WNT protein (WNT3A) to stabilize beta-catenin; and 2) Noggin, which is a bone morphogenetic protein inhibitor. Noggin mutations in unrelated families with proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) have been identified, which have multiple joint fusion as their principal defect.
Spécifications

Spécifications

Q13253
Protein with no preservative
46 kDa
Purified
HEK293 cells
RUO
NOG; Noggin; Noggin precursor; noggin; LOW QUALITY PROTEIN: noggin; SYM1; symphalangism 1 (proximal); SYNS1; SYNS1A
NOG
Protein
Recombinant
-20°C
HEK293 cells
≥ 95% by SDS-PAGE gel and HPLC analyses.
Control, Bioactivity
9241
Human Noggin
2 x 500 μg
-20°C
<1 EU/μg
Noggin
Determined by its ability to inhibit 5.0 ng/ml of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrogenic cells. The expected ED50 for this effect is 2.0-3.0 ng/ml of Noggin.
Unconjugated
QHYLHIRPAP SDNLPLVDLI EHPDPIFDPK EKDLNETLLR SLLGGHYDPG FMATSPPEDR PGGGGGAAGG AEDLAELDQL LRQRPSGAMP SEIKGLEFSE GLAQGKKQRL SKKLRRKLQM WLWSQTFCPV LYAWNDLGSR FWPRYVKVGS CFSKRSCSVP EGMVCKPSKS VHLTVLRWRC QRRGGQRCGW IPIQYPIISE CKCSC
Determined by its ability to inhibit 5.0 ng/ml of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrogenic cells. The expected ED50 for this effect is 2.0-3.0 ng/ml of Noggin.
Lyophilized
missing translation for 'recommendations'

missing translation for 'recommendations'

Videos
FDS
Documents

Documents

Promotions

Promotions